Safe and Timely Antithrombotic Removal (STAR) Registry

This registry will capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb for the removal of antithrombotic agents.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hemorrhage, Surgical Blood Loss, Postoperative Blood Loss, Surgical Hemorrhage Hemorrhage Postoperative Intraoperative Complications Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications Postoperative Hemorrhage

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Universitätsklinikum Graz, Graz, Austria

About this study

The STAR Registry will collect patient-level clinical data on antithrombotic removal with CytoSorb. The decision to use CytoSorb in this clinical setting is based on the clinical rationale of mitigating the high risk of bleeding events that is directly linked to the presence of the antithrombotic agent. This registry is to capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb. Data of retrospective and prospective patients will be included in the registry. Safety will be assessed by collection of (at least possibly) device-related adverse events. Data collection is done up to 30 days post-operation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

CytoSorb utilization for antithrombotic removal
Informed consent for prospective registry participation

Exclusion criteria

Use of CytoSorb for purpose other than antithrombotic removal

Treatment and study plan

CytoSorb

Device

Sorbent hemoperfusion system

Primary outcomes

Bleeding complications including requirements for transfusions and other blood products

Time frame: Assessed until postoperative day (POD) 3, date of ICU discharge, or date of death, whatever comes first; on average 3 days

Study contacts

Contact information is provided by the study sponsor or research team.

Cindy Rechner, PhD

CONTACT

[email protected]

+49 30 654 99 145

Robert Wilke

CONTACT

[email protected]

+49 30 654 99 145

Sponsors and collaborators

Lead sponsor

CytoSorbents, Inc

Industry

Registry information

Official study title

Safe and Timely Antithrombotic Removal (STAR) Registry: International Registry on the Use of CytoSorb for Removal of Antithrombotic Agents in the Acute Hospital Setting

Important dates

Study start: 2021
Primary completion: 2025
Study completion: 2025
First posted: Oct 14, 2021
Registry last updated: Jul 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed